Editor's Summary
13 October 2005
Off-target but on message
The anticancer drug imatinib mesylate (Gleevec) is a success. Targeted at BCR-ABL protein, a cause of chronic myeloid leukaemia, it is proving itself clinically. But it is also being used to treat gastrointestinal stromal tumour. Gleevec, it turns out, targets more than just the protein it's supposed to. Does this mean that 'promiscuous' drugs, selective but not too fussy about which proteins they bind to, are the ideal to aim for?
News Feature: Neuroscience: The maestro of minds
With a mathematician's logic and the perfectionism of a concert pianist, Nikos Logothetis is making waves in cognitive neuroscience — and putting the German town of Tübingen on the scientific map. Alison Abbott pays him a visit.
doi: 10.1038/437946a
